Navigation Links
For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe
Date:12/15/2009

WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

The new Special European Physician & Payer Forum report entitled European Trends in Targeted Therapies in Breast Cancer: A Clinician and Payer Perspective on the Current and Future Uptake finds that, despite not having a HER2 (human epidermal growth factor receptor-2) status label restriction in Europe, most surveyed oncologists reserve Avastin for HER2-negative patients, particularly for patients with triple negative breast cancer. Avastin is at risk of losing significant patient share to Sanofi-Aventis' novel agent BSI-201, which is expected to be approved for triple negative breast cancer on the basis of an improvement in overall survival.

According to the report, in the surveyed European countries where Avastin is reimbursed, Avastin is used in between 16 percent (in Italy) and 38 percent (in France) of first-line metastatic breast cancer patients and between 8 percent (in Italy) and 27 percent (in France) of second-line metastatic breast cancer patients. Through 2010, Avastin's patient share will increase to between 25 percent (in Italy and Spain) and 35 percent (in France) in the first-line treatment setting and between 17 percent (in Italy) and 36 percent (in France) in the second-line. This equates to a potential 30 percent increase in Avastin sales over the next 12 months.

The report also finds that reimbursement of targeted therapies for breast cancer varies significantly between the European countries surveyed.

"Among the four major European markets that reimburse Avastin--Germany, France, Italy and Spain--Italy has the greatest percentage of eligible patients who do not receive Avastin treatment for breast cancer due to cost," said Decision Resources Analyst Niamh Murphy, Ph.D. "Additionally, in the United Kingdom, Avastin is not reimbursed through the National Health Service."

European Trends in Targeted Therapies in Breast Cancer: A Clinician and Payer Perspective on the Current and Future Uptake is based on surveys with 224 oncologists and interviews with 20 hospital-based payers in Germany, France, Italy, Spain and the United Kingdom. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:

    Decision Resources              Decision Resources, Inc.
    Christopher Comfort             Elizabeth Marshall
    781-296-2597                    781-296-2563
    ccomfort@dresources.com         emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
(Date:8/2/2017)... Ore. , Aug. 2, 2017  Life Flight Network ... Agreement. The agreement improves patient care and operational efficiency for ... Springfield , Cottage Grove , ... level medical transportation. PeaceHealth and Life Flight Network work collaboratively ... available during transport, or when a time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... a highly specialized asset-light logistics provider of complex transport solutions for mission-critical ... to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... handheld devices. Through an educational webinar, they will present the line of epMotion ... to learn how easy you can automate everyday pipetting tasks. , Ideal for ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance ... to communities throughout the greater DC region, is inaugurating a “New Leash On ... local animals and training them to be companions for veterans in need. , ...
Breaking Medicine News(10 mins):